- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797690
Effectiveness of Percutaneous Needle Aponeurotomy (EFAPAD)
Effectiveness of Percutaneous Needle Aponeurotomy for Dupuytren's Disease: a Multicenter, Randomised, Non-inferiority Trial, With Surgery as Comparator
The main objective is to investigate if percutaneous needle aponeurotomy is non-inferior to open surgery using aponeurectomy in treatment of flexion contracture due to Dupuytren's disease.
Our hypothesis is that percutaneous needle aponeurotomy has suitable efficacy and safety profile for large application in the treatment of Dupuytren's disease and that it is consequently able to drastically reduce the need of open surgery in this indication.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Scientific justification:
Dupuytren's disease is a world-wide musculoskeletal disorder. It consists in fibrosis of the palmar aponeurosis that can induce disabling flexion contracture of the metacarpophalageal or proximal interphalangeal joints. Treatment modalities of flexion contracture include open surgery, percutaneous needle aponeurotomy and collagenase. Collagenase is not available in France. Aponeurectomy, that is also called fasciectomy, is the main open surgical technique, and open surgery is the most frequently used treatment in Dupuytren's disease. Percutaneous needle aponeurotomy is recommended as a nonsurgical treatment for Dupuytren's disease. It is a minimally invasive procedure. Its most largely accepted indication is Dupuytren's disease with metacarpophalageal joint involvement. However, percutaneous needle aponeurotomy has been successful for metacarpophalageal or proximal interphalangeal joint involvement, in nonadvanced and in advanced Dupuytren's disease. A model analysis recently demonstrated that replacing open surgery with percutaneous needle aponeurotomy could save more than 50% of the total hospitalization costs for the disease.
Percutaneous needle aponeurotomy therefore appears as a unique minimally invasive approach for Dupuytren's disease. It could become a valuable alternative to open surgery. The hypothesis is that percutaneous needle aponeurotomy has suitable efficacy and safety profile for large application in the treatment of Dupuytren's disease and that it is consequently able to drastically reduce the need of open surgery in this indication.
Practical procedure:
Patients addressed to the consultation of the hand surgery centers for Dupuytren's disease will be prospectively selected, included, randomized, treated using percutaneous needle aponeurotomy or open surgery within six weeks after randomization, and followed at 1 week, 1, 3,12, 24 and 36 months after treatment. Assessment of efficacy will be blinded. Assessment of complications will be done by an unblinded assessor.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Johann BEAUDREUIL, PUPH
- Phone Number: +33 1 49 95 88 28
- Email: johann.beaudruil@aphp.fr
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- Hopital LARIBOISIERE - Rhumatologie
-
Contact:
- Johann BEAUDREUIL, PUPH
- Phone Number: 01 49 95 88 28
- Email: johann.beaudreuil@aphp.fr
-
Paris, France, 75002
- Active, not recruiting
- Centre d'Imagerie Médicale Bachaumont Paris Centre
-
Paris, France, 75010
- Active, not recruiting
- Hopital LARIBOISIERE - Radiologie
-
Paris, France, 75016
- Recruiting
- JOUVENET - Orthopédie, chirurgie de la main et du membre supérieur
-
Contact:
- ERIC ROULOT, PH
- Phone Number: 01 42 15 42 33
- Email: secretaire.roulot@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Ascertained Dupuytren disease: palpable fibrotic nodule or cord developed from the palmar aponeurosis, flexion contracture of a metacarpophalangeal or proximal interphalangeal joint.
- Presence of at least one flexion contracture of a metacarpophalangeal joint of the hand due to Dupuytren's disease and > or = 20°
- Written informed consent signed by the patient
- Patient affiliated to the social security
Exclusion Criteria:
- Presence of other musculoskeletal disorders of the hand than Dupuytren's disease: known inflammatory rheumatic disease of the hand, clinical signs of inflammatory rheumatic disease of the hand, MP or PIP pain at inclusion visit.
- Previous surgery of the hand to be treated resulting in functional limitation or limitation of finger mobility
- Any other pathological condition or limited range of motion in the finger to be treated
- Psychiatric status precluding patient evaluation; vulnerable persons; adults under legal protection order or incompetent, physically or mentally incapable of giving his consent.
- Pregnant or beastfeeding women
- Participation in another interventional trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Percutaneous needle aponeurotomy
It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia.
The procedure can be repeated as required during the same session.
One to three sessions with at least one-week interval are usually sufficient and will be allowed.
It will be performed in outpatient setting by a senior physician experienced in the procedure.
End of treatment will be considered as the last session of needle aponeurotomy.
|
It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia.
The procedure can be repeated as required during the same session.
One to three sessions with at least one-week interval are usually sufficient and will be allowed.
It will be performed in outpatient setting by a senior physician experienced in the procedure
|
Active Comparator: Open surgery with limited aponeurectomy
It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay).
Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy).
End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
|
It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay).
Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metacarpophalangeal joint contracture during passive extension
Time Frame: at 3 months after treatment
|
Expressed in degrees, using low energy computed tomography for blinded assessment (computed tomography imaging will be analysed by a blinded assessor not involved in the treatment).
Baseline will be Metacarpophalangeal joint contracture during passive extension the day of the treatment, before any treatment
|
at 3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metacarpophalangeal joint contractures during passive and active extension
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
Expressed in degrees using clinical goniometry, and patient wearing white opac gloves to ensure blinded assessment.
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
Main metacarpophalangeal joint contracture during passive extension,
Time Frame: at 36 months after treament
|
Expressed in degrees, using low energy computed tomography, for blinded assessment (computed tomography imaging will be analysed by a blinded assessor not involved in the treatment).
|
at 36 months after treament
|
The clinical success
Time Frame: at 3 months after treament
|
The clinical success is defined as the reduction of flexum to within 0 to 5° during passive extension, using clinical goniometry, for the main metacarpophalangeal joint); Patient will wear white opac gloves to ensure blinded assessment.
|
at 3 months after treament
|
The recurrence
Time Frame: at 12, 24 and 36 months after treament
|
The recurrence is defined as the flexum progression of 20°, during passive extension, using clinical goniometry, after clinical success.
Patient will wear white opac gloves to ensure blinded assessment.
|
at 12, 24 and 36 months after treament
|
The interphalangeal joint contractures during passive and active extension
Time Frame: at 1 week, 1, 3,12, 24 and 36 months after treatment
|
Expressed in degrees, using clinical goniometry.
Patient will wear white opac gloves to ensure blinded assessment.
|
at 1 week, 1, 3,12, 24 and 36 months after treatment
|
The 70% improvement from baseline of the flexion contracture
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The flexion contracture of each treated joint, during passive extension will be assessed by a blinded assessor (Patient will wear white opac gloves).
- Flexion contracture in degrees using goniometry reported as follows: ray Number; metacarpophalangeal angle; interphalangeal angle
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The active range of motion of metacarpophalangeal and proximal interphalangeal treated joints
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The active range of motion of metacarpophalangeal and proximal interphalangeal treated joints will be assessed by a blinded assessor (Patient will wear white opac gloves).
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The functional limitation using Quick DASH questionnaire
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The patient will fill out the auto-questionnaire.
The blinded assessor will calculate the score (0 to 100, with highest value indicating highest disability).
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The URAM scale
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The patient will fill out the auto-questionnaire.
The blinded assessor will calculate the score (0 to 45, with highest value indicating highest disability).
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The patient satisfaction on a 0-100 mm visual analog scale
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The assessor will ask the patient the following question: "How would you rate satisfaction about the treatment you underwent in the study?"
Patients will be asked to mark the level of their satisfaction on a l00-mm, nonhatched VAS scale marked at one end as "not satisfied" and at the other as "completely satisfied''
|
at 1 week, 1, 3, 12, 24 and 36 months after treatment
|
The number of secondary and repeated treatments
Time Frame: at 12, 24 and 36 months after treatment
|
The number of secondary or repeated open surgeries and percutaneous needle aponeurotomy will be recorded by the unblinded assessor.
|
at 12, 24 and 36 months after treatment
|
Complications and adverse events for primary treatment
Time Frame: at the treatment time, and at 1 week, 1, 3, 12, 24 and 36 months;
|
The number and the types of complications and adverse events for primary open surgery and first line percutaneous needle aponeurotomy will be collected by an unblinded assessor.
|
at the treatment time, and at 1 week, 1, 3, 12, 24 and 36 months;
|
Complications and adverse events for secondary treatment
Time Frame: at the treatment time, at 12, 24 and 36 months;
|
The number and the types of complications and adverse events for secondary open surgery and percutaneous needle aponeurotomy will be collected by an unblinded assessor.
|
at the treatment time, at 12, 24 and 36 months;
|
The post-interventional pain and needs
Time Frame: at 1 week, 1, 3, 12, 24 and 36 months
|
The post-interventional pain and needs of nursing, splinting, medication, physiotherapy,sick leave, time return to regular activities using a patient diary.
These datas will be collected by the unblinded assessor.
|
at 1 week, 1, 3, 12, 24 and 36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Johann BEAUDREUIL, PUPH, APHP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P160903J
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dupuytren Disease of Finger
-
University of MinnesotaRecruitingDupuytren Contracture | Dupuytren Disease of Finger | Dupuytren's Disease | Dupuytren Disease of Palm and Finger | Dupuytrens Contracture of Both Hands | Dupuytren's Disease of Palm of Right Hand | Dupuytren's Disease of Palm of Left Hand | Dupuytren Contracture of Right Palm | Dupuytren Contracture... and other conditionsUnited States
-
Region SkaneActive, not recruitingDupuytren Disease of FingerSweden
-
prof. dr. Ilse DegreefActive, not recruitingDupuytren Contracture | Dupuytren Disease of Palm and FingerBelgium
-
Haukeland University HospitalCompletedDupuytren Disease of Palm and Finger, With ContractureNorway
-
University of CalgaryUnknownDupuytren Contracture | Dupuytren's Disease of FingerCanada
-
The Second Hospital of TangshanCompletedSensory Restoration of the Reconstructed Finger Pulps | Cold Intolerance of the Reconstructed Finger | Pain of the Reconstructed FingerChina
-
The Second Hospital of TangshanChinese PLA General HospitalCompletedSoft Tissue Defect of the FingerChina
-
The Second Hospital of QinhuangdaoCompletedFinger Fracture | Closed Fracture of FingerChina
-
National and Kapodistrian University of AthensCompletedSurgical Release of Ai Pulley Trigger Finger
-
The Second Hospital of QinhuangdaoCompletedClosed Fracture of Finger | Finger Fracture OpenChina
Clinical Trials on Percutaneous needle aponeurotomy
-
Sunnybrook Health Sciences CentreUnknown
-
University of CalgaryUnknownDupuytren Contracture | Dupuytren's Disease of FingerCanada
-
University Hospital, AkershusCompleted
-
Tampere UniversityTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsActive, not recruitingDupuytren ContractureFinland
-
University of AlbertaWithdrawnDupuytren ContractureCanada
-
Groupe Hospitalier Diaconesses Croix Saint-SimonCompleted
-
Jose Antonio Garcia VidalUniversidad de MurciaCompleted
-
Universidad de ZaragozaMinistry of Health, Kuwait; Universidad San JorgeCompletedPlantar Fascitis | Myofacial Pain Syndromes | Trigger Point Pain, MyofascialKuwait
-
University of AlcalaRecruiting
-
Universidad Rey Juan CarlosRecruitingPosterior Tibial Tendon DysfunctionSpain